# reload+after+2024-01-20 19:45:43.877952
address1§4275 Executive Square
address2§Suite 950
city§La Jolla
state§CA
zip§92037
country§United States
phone§619 592 9775
website§https://www.longboardpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
fullTimeEmployees§32
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Kevin R. Lind', 'age': 47, 'title': 'President, CEO, Secretary & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 961845, 'exercisedValue': 0, 'unexercisedValue': 48783}, {'maxAge': 1, 'name': 'Ms. Brandi L. Roberts CPA, M.B.A.', 'age': 49, 'title': 'Executive VP & CFO', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 610069, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Randall E. Kaye M.D.', 'age': 61, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 629026, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chadwick J. Orevillo MPH', 'title': 'Executive VP & Head of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Megan E. Knight', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven W. Spector J.D.', 'age': 58, 'title': 'Executive VP, Head of Business Development & General Counsel', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Anne M. Danks Ph.D.', 'title': 'VP & Head of Nonclinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gus  Cardenas', 'title': 'VP & Head of Quality Assurance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marco  Peters Ph.D.', 'title': 'VP & Head of Translational Science', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dewey  McLin Ph.D.', 'title': 'VP & Head of Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.084
currency§USD
dateShortInterest§1702598400
forwardEps§-1.97
exchange§NGM
quoteType§EQUITY
shortName§Longboard Pharmaceuticals, Inc.
longName§Longboard Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1615559400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3613b707-ae0b-3b49-aa53-370148927a51
gmtOffSetMilliseconds§-18000000
targetHighPrice§55.0
targetLowPrice§13.0
targetMeanPrice§32.57
targetMedianPrice§32.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§8.346
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
